Skip to content

Our vision

Enabling precision medicine to save millions of lives!

WARNING: Beware of Scam Using Our Company Name for Fake Job Interviews
WARNING: Beware of Scam Using Our Company Name for Fake Job Interviews

Who We Are

Experts in single-cell science, -omics analytics, and AI.

Scailyte is a pioneer in leveraging artificial intelligence for deep insights from high-dimensional cellular data, with foundational expertise in single-cell analysis. Born as an ETH Zürich spin-off in 2017, we are now a clinical-stage precision medicine company dedicated to developing our own pipeline of breakthrough diagnostic and companion diagnostic (CDx) solutions. Our mission is to transform healthcare in complex diseases like cancer and autoimmune disorders by ensuring the right patient receives the right treatment. We achieve this by applying our best-in-class, explainable AI platform, ScaiVision, to unique multimodal datasets (including single-cell, spatial, immune profiling, and other omics), often enriched through our clinical network. Our discoveries directly fuel our product development, and all our work is underpinned by high industry standards and driven by a great, diverse, and complementary team working in tight synergy to translate cutting-edge science into clinical impact.

Mission

Our mission is to advance precision medicine with single-cell technologies, artificial intelligence, and multiomics analysis.

Our Values

Our Values Infographic

Vision

To save lives by enabling precision medicine.

Meet Our Team

LinkedInCreated with Sketch.

Dr. Peter Nestorov

Founder & Chief Executive Officer

Peter holds a PhD in Genetics from the University of Basel and a degree in Biochemistry from the University of Tübingen. He has been working in the emerging single-cell analysis market since 2015 and this gave him the inspiration to start Scailyte as co-founder and CEO in 2017.

Tim Foley​

Tim Foley

Chief Business Officer

Tim, with over 20 years of experience in business development and deal-making primarily at Takeda and Astellas, now focuses on precision medicine, driving partnerships and funding in healthtech. Holding an MBA from DePaul’s Kellstadt Graduate School of Business, his expertise and dynamic approach are set to expand our biomarker discovery platform into the American market. Tim joined Scailyte as a Chief Business Officer in 2024.

LinkedInCreated with Sketch.

Dr. Sarah Carl

Director Data Science

Sarah holds a PhD in Genetics from the University of Cambridge. She worked as a bioinformatician at the Friedrich Miescher Institute in Basel, Switzerland, for four years before joining Scailyte. Sarah joined Scailyte as a data scientist in 2018 and now serves as Director of Data Science.

LinkedInCreated with Sketch.

Anna Dimitrova, ACCA

Chief Financial Officer

Anna is an ACCA graduate with a Master’s degree in Finance and Banking from Sofia University. Previously, she worked as a finance manager in a fast growing company, auditor in KPMG and business consultant in PwC. Anna joined the Scailyte team in 2018.

LinkedInCreated with Sketch.

Dennis Göhlsdorf

Machine Learning Engineer
Dennis is a multi-disciplinary professional with degrees in both Biochemistry and Computer Science obtained from the University of Tuebingen. He earned his PhD at the Institute of Neuroinformatics at ETH Zurich / University of Zurich. From 2013 until 2016, he worked as a Software Engineer at Google Germany, focusing on Image processing algorithms. He co-founded Scailyte in 2016 and is currently working in the data science team.
LinkedInCreated with Sketch.

Our team

Team Graph

Join the Scailyte team
Are you ready to help us transform biomedical research and healthcare? Please send us your CV, and your letter of motivation to join Scailyte, in an email to: careers@scailyte.com

Become part of something great

To achieve our mission, we are looking for smart, passionate and dedicated individuals who share our values by dreaming big, to join our growing, energetic and fun team. We offer flexible working schedules and location.

Join the Scailyte team
Are you ready to help us transform biomedical research and healthcare? Please send us your CV, and your letter of motivation to join Scailyte, in an email to: careers@scailyte.com

Recent News

Scailyte and Sanofi Collaboration Solves Critical Manufacturing Challenge for NK Cell Therapy, New Paper Reveals

Scailyte's AI-driven ScaiVision™ platform successfully identified a predictive biomarker for manuf...

Read more

Recent News

Scailyte Awarded CHF 800K Innosuisse Grant to Drive Precision Medicine in Inflammatory Bowel Disease (IBD)

Project AIomics will unite Scailyte's AI discovery platform with the Swiss IBD Cohort and Universit...

Read more

Recent News

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Read more

Recent News

Scailyte Strengthens Its Leadership

Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Dar...

Read more

Recent News

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings str...

Read more

Recent News

Scailyte Extends Series A to USD 8 Million

We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...

Read more

Recent News

Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs

We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...

Read more

Recent News

Scailyte and MaxiVAX Solve Clinical Challenges with Data-Driven Collaboration

Scailyte and MaxiVAX, two cutting-edge precision medicine organizations, proudly announce their coll...

Read more

Recent News

01 /04

Scailyte and Sanofi Collaboration Solves Critical Manufacturing Challenge for NK Cell Therapy, New Paper Reveals

Scailyte's AI-driven ScaiVision™ platform successfully identified a predictive biomarker for manuf...

Read more

Scailyte Awarded CHF 800K Innosuisse Grant to Drive Precision Medicine in Inflammatory Bowel Disease (IBD)

Project AIomics will unite Scailyte's AI discovery platform with the Swiss IBD Cohort and Universit...

Read more

Recent News

02 /04

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Read more

Scailyte Strengthens Its Leadership

Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Dar...

Read more

Recent News

03 /04

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings str...

Read more

Scailyte Extends Series A to USD 8 Million

We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...

Read more

Recent News

04 /04

Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs

We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...

Read more

Scailyte and MaxiVAX Solve Clinical Challenges with Data-Driven Collaboration

Scailyte and MaxiVAX, two cutting-edge precision medicine organizations, proudly announce their coll...

Read more

Recent News

Dr. Peter Nestorov

Founder & Chief Executive Officer

Co-founder and Chief Executive Officer of Scailyte. He holds a PhD in genetics from the University of Basel and a degree in Biochemistry from the University of Tübingen.

During his PhD work, Dr. Nestorov pioneered the development and application of methods for single-cell analysis, which sparked his passion for this technology. In 2015, Dr. Nestorov joined Witec AG as Sales Specialist for single-cell and genomics technologies and successfully introduced the first commercial devices for single-cell analysis on the Swiss Life Science market. The interaction with biomedical researchers and the technological insight inspired Dr. Nestorov to start Scailyte and unlock the full clinical potential of single-cell data.

Mobile Menu Closed

Dr. Sarah Carl

Lead Data Scientist
is managing the Data Science division of Scailyte. She holds a PhD in Genetics and a Master’s degree in Developmental Biology from the University of Cambridge. Before joining Scailyte she was a post-doc and bioinformatician at the Friedrich Miescher Institute for Biomedical Research in Basel. At Scailyte she is leading the development of new applications and features of the internal data analysis platform, ScaiVision, and the data analysis of the clinical programmes.
Mobile Menu Closed

Anna Dimitrova, ACCA

Director Finance & Ops
Is the Director of Finance and Operations at Scailyte. She is an ACCA graduate with a Master’s degree in Finance and Banking from Sofia University. Before joining Scailyte she worked as Senior Audit Assistant at KPMG, Senior Business Consultant at PwC and as Finance Manager in a fast growing company in Bulgaria. At Scailyte she leads the finance, administration and internal operations of the company.

Pascal Winnen

CEO Hemex AG & Scailyte Board of Directors

Pascal is a co-founder and the CEO of HEMEX, a pharmaceutical, biotech and medical device consulting firm with offices in Switzerland, Germany and the USA. He holds a bachelor’s degree in Telecommunication Technologies from the University of Leuven (Belgium) and a master’s degree in Clinical Research from the Donau University in Krems (Austria). Pascal worked in various positions in the pharmaceutical and medtech industry.

From 2011 to 2015, Pascal worked for Finox Biotech, bringing one of the first biosimilar fertility treatments to the market in the EU and leading to the successful acquisition by Gedeon Richter for CHF 190 million. With his consulting firm HEMEX, Pascal has invested in multiple innovative life science startups, where he also advises on regulatory, clinical and marketing strategies, either as a senior consultant or as a board member.

Mobile Menu Closed

Dominique Mégret

Head of Swisscom Ventures & Scailyte Board of Directors
Dominique Mégret is head of Swisscom Ventures, which he started in 2007. He joined Swisscom in 2002 as head of the Group Strategy unit. Previously, Dominique Mégret was an entrepreneur in the United Kingdom, a strategy consultant in the European telecom industry and country manager for an IT company in Germany. He currently serves on the boards of Scailyte AG and Bloom SA. He is also an observer on the boards of Sophia Genetics and AVA Women.
Mobile Menu Closed

Prof. Dr. Manfred Claassen

Founder & Chief Scientific Advisor AI & Single-Cell Analysis
Co-founder and Chief Scientific Advisor at Scailyte. He holds degrees in both Biochemistry and Computer Science from the University of Tübingen and a PhD in the design and validation of proteome measurements from the ETH Zurich. He continued his academic path as a postdoctoral researcher at Stanford University’s Artificial Intelligence Lab focusing on research in machine learning for high dimensional single-cell biology, he moved back to Switzerland as an Assistant Professor at the ETH. During this time, the idea of establishing a company specialising in digital healthcare was conceived. Dr. Claassen was instrumental in conceptualizing the new company. He is now professor for clinical bioinformatics at the University of Tübingen, Germany in parallel with his role as scientific consultant for Scailyte.
Mobile Menu Closed